There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I was a bit worried last week’s ...

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Scotland’s rich culinary heritage ​is vital for the country’s economy – but it needs to be future-proofed, writes Dr Liz ...

Dan Heapy brings strategic marketing expertise to critically assess the approaches taken by the biotech companies – and offers recommendations for future biotech development. With the ever ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

With just $3.9 million left in the bank—which the biotech expects to run out within the next three months—Vincerx is left to “reassess its strategic options.” These could span the usual ...

Food safety is a critical global concern, impacting public health, trade, and the environment. As the world’s population grows and supply chains become increasingly complex, ensuring food safety ...